Pharsight

Endo Pharms Inc patents expiration

1. Aveed patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718640 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
Mar, 2027

(3 years from now)

US8338395 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
May, 2027

(3 years from now)

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 05 March, 2014

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...

Dosage: INJECTABLE;INTRAMUSCULAR

How can I launch a generic of AVEED before it's drug patent expiration?
More Information on Dosage

AVEED family patents

Family Patents

2. Megace Es patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9107827 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(6 months from now)

US9101549 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(6 months from now)

US9101540 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(6 months from now)

US9040088 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(6 months from now)

US7101576 ENDO PHARMS INC Nanoparticulate megestrol formulations
Apr, 2024

(6 months from now)

Drugs and Companies using MEGESTROL ACETATE ingredient

Market Authorisation Date: 05 July, 2005

Treatment: Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids)

Dosage: SUSPENSION;ORAL

How can I launch a generic of MEGACE ES before it's drug patent expiration?
More Information on Dosage

MEGACE ES family patents

Family Patents

3. Nascobal patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8940714 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Feb, 2024

(4 months from now)

US7404489 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Mar, 2024

(5 months from now)

US9415007 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Jul, 2024

(9 months from now)

US7229636 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Aug, 2024

(9 months from now)

US7879349 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Aug, 2024

(9 months from now)

US8003353 ENDO PHARMS INC Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
Aug, 2024

(9 months from now)

Drugs and Companies using CYANOCOBALAMIN ingredient

Market Authorisation Date: 31 January, 2005

Treatment: Cyanocobalamin administration through nasal infusion; Supplement for vitamin b12 deficiencies; Nasal administration of cyanocobalamin

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of NASCOBAL before it's drug patent expiration?
More Information on Dosage

NASCOBAL family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic